Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)

What is known and objectiveHypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus-treated patient and provide recommendations for its management. Case summaryThe patient was a 70-year-old woman, being treated with everolimus for a pancreatic neuroendocrine tumour (pNET). She developed severe HTG to a maximum of 969mg/dL after 22months of therapy. Treatment with fenofibrate rapidly normalized triglyceride (TG) levels. What is new and conclusionSevere HTG may occur in everolimus-treated patients. Prescription of the appropriate therapy can allow patients to continue this medication.